At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating semaglutide and sitagliptin for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 504 participants across 83 sites in 10 countries.
Detailed Summary
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Austria, Belgium, Brazil, Egypt, Norway, South Korea, Switzerland, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartSep 2016
Primary CompletionFeb 2018
Study CompletionMar 2019
TodayJul 2026
First PostedJul 29, 2016
Enrollment StartSep 20, 2016
Primary CompletionFeb 28, 2018
Study CompletionMar 27, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago
Interventions
semaglutidedrug
Oral administration once-daily.
sitagliptindrug
Oral administration once-daily.